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Abstract
Background Real-world evidence is lacking on the impact
of bevacizumab added to carboplatin/paclitaxel (Bev ?
CP) therapy versus CP alone for patients with non-squa-
mous non-small cell lung cancer (NS-NSCLC), particularly
in those excluded from clinical trials.
Methods This is a retrospective electronic medical record
analysis of patients who received first-line therapy with
Bev ? CP or CP between 1 October 2006 and 30 June
2013. We identified four subsets: elderly patients (C65
years), patients with brain/central nervous system (CNS)
metastases, patients with Eastern Cooperative Oncology
Group performance status (ECOG PS) C2, and patients
receiving anticoagulation. We used descriptive statistics to
describe patient characteristics and treatment patterns and
evaluated progression-free survival (PFS) and overall sur-
vival (OS) using survival analyses.
Results The study included 431 patients (Bev ? CP: 231;
CP: 200). The Bev ? CP cohort was more likely to receive
four or more cycles of induction therapy (72 vs. 50 %) and
was more likely to receive maintenance therapy (45 vs. 21
%) than patients receiving CP. In the overall population,
median PFS and OS were significantly longer in the Bev ?
CP cohort than in the CP cohort: 6.7 vs. 5.1 months (hazard
ratio [HR] 0.74; 95 % confidence interval [CI] 0.59–0.92;
p = 0.008) and 11.9 vs. 9.0 months (HR 0.57; 95 % CI
0.44–0.73; p\0.001), respectively. Treatment with Bev ?
CP in patients aged C65 years and in those with brain/CNS
metastases was also associated with a significant risk
reduction in PFS (35 and 51 %, respectively; p\ 0.05 for
both) and OS (46 and 62 %, respectively; p\0.05 for both)
compared with CP alone.
Conclusion Bev ? CP is associated with a significant
improvement in PFS and OS in patients with NS-NSCLC
and in subsets with brain/CNS metastases and those aged
C65 years.
Key Points
Despite that the current guidelines for the treatment
of non-small cell lung cancer (NSCLC) endorse
bevacizumab added to the chemotherapy backbone
of carboplatin and paclitaxel, there is a lack of
published real-world evidence documenting the use
of this combination in subpopulations either
excluded or under-represented in clinical trials.
Our study suggested that bevacizumab, when added
to carboplatin and paclitaxel in a real-world setting,
is associated with a survival advantage; this
advantage is also seen in patients with brain/central
nervous system metastases and in patients aged C65
years.
Understanding what populations stand to benefit in a
real-world setting from the use of bevacizumab may
influence future guideline development and provide
direction regarding outcomes of interest in future
trials in NSCLC.
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1 Introduction
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer-related deaths in the USA, accounting for[25 %
of all cancer-related deaths in both men and women [1]. At
diagnosis, 70 % of patients have advanced or metastatic
disease, and systemic chemotherapy is the main treatment
modality employed to prolong survival [2]. Historically,
platinum-based doublets have been the backbone of treat-
ment for advanced or metastatic NSCLC, with carboplatin
and paclitaxel having a toxicity advantage over other
platinum-based comparators [3, 4]. More recently, histol-
ogy has been elucidated as a major driver in determining
sensitivity to specific chemotherapy combinations [5, 6].
A study by the Eastern Cooperative Oncology Group
(ECOG), study ECOG 4599, revealed that the addition of
bevacizumab to the carboplatin/paclitaxel (Bev ? CP)
backbone with continued bevacizumab maintenance has a
survival advantage of approximately 2 months versus car-
boplatin/paclitaxel (CP) alone in non-squamous NSCLC
(NS-NSCLC); this advantage is even more pronounced in
patients with adenocarcinoma histology [5, 7]. A second
European trial, AVAiL, found that the addition of beva-
cizumab at two different doses to another platinum back-
bone, gemcitabine and cisplatin, significantly prolonged
progression-free survival (PFS) but was not powered to
detect an overall survival (OS) advantage [8]. While these
studies have placed bevacizumab in combination with a
platinum-based regimen among the recommended first-line
therapies for NS-NSCLC [9], the exclusion criteria
employed by these trials limit the evidence regarding the
efficacy of bevacizumab in a real-world setting. Specifi-
cally, patients with brain or central nervous system (CNS)
metastases, poor performance status (PS; i.e., ECOG PS
C2), and those receiving therapeutic anticoagulation were
excluded. For the population using bevacizumab with
anticoagulants, no increased risk has been observed in
those with non-squamous histology based on the retro-
spective analysis of clinical trial data [10, 11]. However,
real-world analyses evaluating whether the use of antico-
agulants in patients with NS-NSCLC reduces the effec-
tiveness of bevacizumab are lacking. Therefore, this subset
was included as a subpopulation of interest in the current
study.
Further, in the ECOG 4599 trial, although [40 % of
patients were aged C65 years, subset analysis revealed this
population had more limited benefit from the addition of
bevacizumab than their younger counterparts: hazard ratio
(HR) for death: 0.89 (95 % confidence interval [CI]
0.70–1.14) vs. 0.71 (95 % CI 0.58–0.88), respectively [7].
More recent literature has suggested that the addition of
bevacizumab to chemotherapy is beneficial for patients
aged up to 75 years, but the benefit in those aged C75 years
is unconfirmed [12–14].
With the increasing number of therapeutic options,
considerable effort has been directed toward identifying
optimal therapies for specific segments of the NS-NSCLC
patient population given the paucity of evidence in this
area. The goal of this retrospective cohort study was to
assess real-world utilization and outcomes of patients with
advanced-stage NS-NSCLC receiving first-line Bev ? CP
or CP without bevacizumab. Within the full study popu-
lation, results were also stratified to address information
gaps in the literature for four subpopulations: elderly
patients aged C65 years, patients with brain or CNS
metastases, patients with an ECOG PS C2, and patients
with recent or ongoing anticoagulant therapy.
2 Methods
2.1 Data Source
For this study, we used data from the International
Oncology Network (ION) electronic medical record (EMR)
database between April 2006 and July 2013. ION is a
geographically diverse physician services network, the
membership of which represents over half of the private
practice oncologists in the USA. The ION EMR database
includes both standardized EMR tables and electronic
patient progress notes. Data for this study were obtained
from the standardized tables; a comprehensive manual
chart review of progress notes supplemented information
from the tables. Data collected included patient character-
istics regarding diagnosis, age, sex, ECOG PS, smoking
status, comorbidities, anticoagulant use, vitals (height,
weight, blood pressure, etc.) and disease/treatment char-
acteristics such as extent of disease, treatment plan
schedule, treatment response, and disease progression.
Vital status, including date of death, was supplemented
with data from the Social Security Death Master File.
2.2 Study Design and Population
This was a retrospective cohort analysis of patients with
advanced or metastatic NS-NSCLC who received first-line
induction therapy with Bev ? CP or CP between 1 October
2006 and 30 June 2013. The start date of first-line induction
therapy was defined as the study index. A 6-month period
before the index was used as the baseline period to char-
acterize the study population. Patients were then followed
from index until the earliest of last recorded visit date, date
of progression or death, or end of study period (31 July
2013). All patients were required to have a minimum of 1
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month of follow-up after index, which excluded patients
who progressed or died within the first 30 days following
index and ensured receipt of at least one cycle of first-line
induction therapy.
Patients were required to be aged C18 years, have a
confirmed diagnosis of stage IIIB or stage IV NS-NSCLC,
have confirmed non-squamous histology, and have
received first-line induction therapy within 180 days of
diagnosis of advanced/metastatic disease. Patients were
excluded if they had evidence of other primary malignan-
cies, had incomplete progress notes, or had received other
chemotherapy or investigational agents during first-line
induction therapy. Additionally, patients with concurrent
radiotherapy during induction therapy, indicating radio-
sensitizing chemotherapy, were also excluded.
The four subpopulations of interest were defined as
follows: (1) elderly patients aged C65 years at index; (2)
patients with brain or CNS metastases at index or any time
during the 6-month baseline period, defined as the presence
of a diagnosis code for distant metastases in the brain
(International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] codes 198.3, 198.4) in
the standardized EMR tables or the presence of iterations
of the following terms in the progress notes: ‘brain
metastases,’ ‘brain mets,’ ‘CNS metastases,’ or equivalent
terms; (3) patients with an ECOG PS score of C2; ECOG
score closest to index was captured and only scores within
3 months before or after index were captured; and (4)
patients with recent or ongoing anticoagulant therapy,
defined as the presence of oral or parenteral anticoagulants
in the progress notes at index or within 3 months before or
1 month after index.
2.3 Outcome Measures
The primary outcome measures were PFS and OS. PFS was
defined as the time from index to progression, which was
assessed within the progress notes as mention of disease
progression or mixed response, initiation of hospice, or
death. Patients who were lost to follow-up or who reached
the end of the study period without evidence of progression
or death event were censored for the PFS analysis. OS was
defined as the time from first-line therapy initiation to date
of death; patients were only censored if they were lost to
follow-up or reached the end of the observation period (31
July 2013) for the OS analysis.
To characterize treatment patterns, we evaluated the
total number of cycles of induction therapy, the proportion
of patients treated according to label for induction therapy
defined as having four or more cycles, the proportion of
patients treated with maintenance therapy after induction,
and the proportion of patients treated with second-line
therapy. Maintenance therapy was defined as receipt of
therapy after end of induction therapy but before progres-
sion. Second-line therapy was defined as receipt of therapy
after disease progression. Additionally, the discontinuation
rate of both induction and maintenance therapy was also
reported together with reasons for discontinuation and
reasons for not initiating maintenance therapy.
2.4 Statistical Analysis
We used descriptive statistics (frequencies, proportions,
means, medians, standard deviations) to describe patient
demographic/clinical characteristics and treatment patterns
by treatment cohort and inferential statistics to assess dif-
ferences at baseline between cohorts using Chi-squared
tests for categorical variables and t tests for continuous
variables. We used univariate Kaplan–Meier and multi-
variate Cox proportional hazards (PH) regression analyses
to estimate and compare OS and PFS by treatment cohort.
Results of the Kaplan–Meier analyses included median
survival and associated p values based on a log-rank test.
Results of the Cox models were summarized by high-
lighting HRs and associated 95 % CIs for the independent
variables. The Cox PH models adjusted for the following
covariates: age at therapy initiation, sex, geographic
region, payer, year of therapy initiation (before 2009 [ref-
erence] or later), smoking status, ECOG PS score, Charlson
comorbidity index score in the 6 months prior to therapy
initiation, presence of brain or CNS metastasis, and pres-
ence of bone metastasis. We selected the year of therapy
initiation as a covariate because a shift in treatment para-
digm toward more bevacizumab use started in 2009.
3 Results
We identified 4424 patients with NS-NSCLC who initiated
treatment with Bev ? CP or CP between 1 October 2006
and 30 June 2013 (Fig. 1). Of these, 431 (Bev ? CP: n =
231; CP: n = 200) met study inclusion criteria. The
majority of patients were excluded because of a lack of
evidence for metastatic or advanced disease (62.4 %) and
an inability to confirm non-squamous histology (18.3 %)
(Fig. 1). Within the pre-specified subsets, 231 patients
were aged C65 years, 96 had brain/CNS metastases, 57 had
an ECOG PS C2, and 58 were receiving anticoagulation
therapy at initiation of first-line induction therapy with Bev
? CP or CP.
Table 1 summarizes the patient characteristics for the
overall population and by treatment with or without
bevacizumab. The sample was almost evenly split at the
cutoff age of 65 years, with 54 % of the sample aged C65
years. Patients aged C70 years accounted for almost one-
third of the patients, with 16 % aged C75 years. In general,
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patients receiving Bev ? CP were older than patients
receiving CP (66 vs. 64 years; p = 0.045); accordingly, a
higher proportion of patients were aged 65–74 years, but a
similar proportion were aged C75 years. The majority of
the entire study population was male (56 %) with no dif-
ference between cohorts. ECOG PS was not significantly
different between cohorts, with 64 % of the Bev ? CP
cohort and 56 % of the CP cohort classified as ECOG 0 or 1
and 12.1 % of the Bev ? CP group and 14.5 % of the CP
group classified as ECOG C2. The ECOG PS score was
unknown in 24 % of the Bev ? CP group and in 30 % of
the CP group. The Bev ? CP cohort was significantly more
likely than the CP cohort to have bone metastases (55 vs.
38 %; p\0.001) and was less likely than the CP cohort to
have brain/CNS metastases (11 vs. 36 %; p\ 0.001). The
comorbid burden, as measured by the Charlson
4,424 NSCLC patients with first-line therapy with CP Bev between 
10/1/2006 and 6/30/2013
1,665 metastatic/advanced NSCLC at initiation of first-line therapy
735 eligible for inclusion
665 initiated first-line therapy within 180 days of diagnosis
518 eligible patients treated with first-line induction CP±Bev
431 FINAL STUDY POPULATION
Advanced NS-NSCLC treated with first-line CP±Bev
231 Bev+CP
200 CP
2,759 excluded: non-metastatic/advanced disease
930 excluded:
811 squamous histology or non-squamous not confirmed
104 had other primary malignancies
14 had incomplete progress notes
1 age <18 years
70 excluded: ≥180 days between metastasis diagnosis and 
initiation of first-line therapy
147 excluded: other therapies during induction with CP Bev 
31 added other drugs 
7 received investigational agent
67 received concurrent radiation therapy
42 added Bev to later cycles of induction therapy
87 excluded: no minimum 30-day post-index follow-up
82 death or loss to follow-up
5 progression 
231 Elderly
137   Bev+CP
94   CP
96 Brain/CNS metastases
25   Bev+CP
71   CP
57 ECOG PS ≥2
28   Bev+CP
29   CP
58 Anticoagulant use
24   Bev+CP




Fig. 1 Final study population and subpopulations. Bev bevacizumab, CNS central nervous system, CP carboplatin ? paclitaxel, ECOG Eastern
Cooperative Oncology Group, NSCLC non-small cell lung cancer, NS-NSCLC non-squamous non-small cell lung cancer, PS performance status
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Table 1 Demographic and clinical characteristics at baseline
All patients (N = 431) BEV ? CP (n = 231) CP (n = 200) p valuea
Age in years 64.6 ± 9.8 65.5 ± 67.0 63.6 ± 63.0 0.045
Age group, years
18–64 200 (46.4) 94 (40.7) 106 (53.0)
65–69 86 (20.0) 54 (23.4) 32 (16.0)
70–74 75 (17.4) 45 (19.5) 30 (15.0)
C75 70 (16.2) 38 (16.5) 32 (16.0)
Male 239 (55.5) 126 (54.5) 113 (56.5) 0.684
Race/ethnicity 0.010
Caucasian 236 (54.8) 127 (55.0) 109 (54.5)
African American 32 (7.4) 11 (4.8) 21 (10.5)
Asian 2 (0.5) 2 (0.9) 0 (0.0)
Hispanic 2 (0.5) 0 (0.0) 2 (1.0)
Other 4 (0.9) 0 (0.0) 4 (2.0)
Missing 155 (36.0) 91 (39.4) 64 (32.0)
Patient insurance 0.002
Medicaid 22 (5.1) 6 (2.6) 16 (8.0)
Medicare 186 (43.2) 114 (49.4) 72 (36.0)
Other 5 (1.2) 0 (0.0) 5 (2.5)
Private 168 (39.0) 85 (36.8) 83 (41.5)
Missing 50 (11.6) 26 (11.3) 24 (12.0)
Geographic region of practice 0.881
Midwest 91 (21.1) 47 (20.3) 44 (22.0)
Northeast 30 (7.0) 15 (6.5) 15 (7.5)
South 283 (65.7) 153 (66.2) 130 (65.0)
West 27 (6.3) 16 (6.9) 11 (5.5)
Location of metastases
Adrenal glands 77 (17.9) 37 (16.0) 40 (20.0) 0.282
Bone 201 (46.6) 126 (54.5) 75 (37.5) <0.001
Brain 96 (22.3) 25 (10.8) 71 (35.5) <0.001
Contralateral lung 64 (14.8) 37 (16.0) 27 (13.5) 0.464
Liver 81 (18.8) 49 (21.2) 32 (16.0) 0.167
Lymph nodes 232 (53.8) 116 (50.2) 116 (58.0) 0.106
Pericardium 21 (4.9) 8 (3.5) 13 (6.5) 0.144
Pleural surface 90 (20.9) 54 (23.4) 36 (18.0) 0.171
Other 19 (4.4) 5 (2.2) 14 (7.0) 0.015
ECOG PS 0.348
0 99 (23.0) 52 (22.5) 47 (23.5)
1 159 (36.9) 95 (41.1) 64 (32.0)
2 50 (11.6) 24 (10.4) 26 (13.0)
C3 7 (1.6) 4 (1.7) 3 (1.5)
Unknown 116 (26.9) 56 (24.2) 60 (30.0)
Smoking status 0.327
Current smoker 150 (34.8) 80 (34.6) 70 (35.0)
Prior smoker (quit) 214 (49.7) 109 (47.2) 105 (52.5)
Never smoked 47 (10.9) 28 (12.1) 19 (9.5)
Unknown 20 (4.6) 14 (6.1) 6 (3.0)
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comorbidity index, was similar between cohorts. However,
the cohorts differed significantly in the prevalence of
anemia, history of serious bleeding events, weight loss, and
venous thromboembolism, with the Bev ? CP cohort sig-
nificantly less likely to have these conditions at baseline
than the CP cohort.
Similar trends in patient characteristics noted in the
overall population were found in each of the four sub-
populations (data not shown). In general, the elderly pop-
ulation had more comorbidities than the total patient
population. The subpopulation of 96 patients with brain/
CNS metastases was slightly younger than the total popu-
lation (mean age 61 years) and was less likely to have
comorbid conditions.
In the overall population, the Bev ? CP cohort had a
higher average number of chemotherapy cycles (five vs.
four), with a consequently higher proportion treated
according to label, defined as receiving four or more cycles
of therapy (72 vs. 50 %) than the CP cohort (Table 2). The
most common reason for discontinuation of induction
therapy in both the Bev ? CP and the CP cohorts was
disease progression, followed by toxicity.
Less than half of both cohorts received maintenance
therapy after induction, with more than twice the propor-
tion of Bev ? CP patients receiving maintenance therapy
compared with CP patients: 45 vs. 21 % (Table 2). Disease
progression was the primary reason for not receiving
maintenance therapy. For those receiving maintenance
therapies, the majority of the Bev ? CP cohort received
bevacizumab, whereas the majority of the CP cohort
received pemetrexed and erlotinib. Second-line therapy
was initiated in 54 % of Bev ? CP patients and in 44 % of
CP patients, with pemetrexed prescribed most frequently.
These treatment patterns were similar for the other
Table 1 continued
All patients (N = 431) BEV ? CP (n = 231) CP (n = 200) p valuea
BMI 0.344
Underweight 22 (5.1) 8 (3.5) 14 (7.0)
Normal 168 (39.0) 88 (38.1) 80 (40.0)
Overweight 144 (33.4) 80 (34.6) 64 (32.0)
Obese 97 (22.5) 55 (23.8) 42 (21.0)
Charlson comorbidity index score 6.7 ± 0.9 6.7 ± 0.8 6.7 ± 1.1 0.760
Comorbid conditions
Diabetes without end-organ damage 65 (15.1) 34 (14.7) 31 (15.5) 0.821
Hypertension 203 (47.1) 105 (45.5) 98 (49.0) 0.462
COPD 124 (28.8) 70 (30.3) 54 (27.0) 0.450
Congestive heart failure 9 (2.1) 5 (2.2) 4 (2.0) 1.000
Renal insufficiency/failure 10 (2.3) 3 (1.3) 7 (3.5) 0.130
Anemia 10 (2.3) 1 (0.4) 9 (4.5) 0.007
Thrombocytopenia 5 (1.2) 3 (1.3) 2 (1.0) 1.000
History of myocardial infarction 22 (5.1) 13 (5.6) 9 (4.5) 0.596
History of stroke/TIA 10 (2.3) 7 (3.0) 3 (1.5) 0.351
History of bleeding events, serious hemorrhage, recent hemoptysis 29 (6.7) 9 (3.9) 20 (10.0) 0.012
Cerebrovascular, valvular disease 7 (1.6) 3 (1.3) 4 (2.0) 0.709
Connective tissue disease, rheumatologic disorders 10 (2.3) 6 (2.6) 4 (2.0) 0.758
Peripheral vascular disease 18 (4.2) 6 (2.6) 12 (6.0) 0.078
Ulcer disease 5 (1.2) 1 (0.4) 4 (2.0) 0.188
Weight loss 89 (20.6) 33 (14.3) 56 (28.0) <0.001
Cardiovascular disease 76 (17.6) 45 (19.5) 31 (15.5) 0.280
Venous thromboembolism 28 (6.5) 8 (3.5) 20 (10.0) 0.006
Hypercholesterolemia 115 (26.7) 54 (23.4) 61 (30.5) 0.095
Data are presented as n (%) or mean ± standard deviation
BEV bevacizumab, BMI body mass index, COPD chronic obstructive pulmonary disease, CP carboplatin ? paclitaxel, ECOG Eastern Coop-
erative Oncology Group, PS performance status, TIA transient ischemic attack
a p values B 0.05 were bolded and considered statistically significant
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Table 2 Treatment patterns during follow-up in the overall population and elderly subpopulation










Mean (median) number of cycles 5 (4.0) 4 (3.5) 5 (4.0) 5 (4.0)
Patients treated according to label C4 cycles 166 (71.9) 100 (50.0) 98 (71.5) 49 (52.1)
Discontinued induction therapy a 116 (50.2) 117 (58.5) 63 (46.0) 58 (61.7)
Reasons for discontinuation
Disease progression 61 (52.6) 72 (61.5) 25 (39.7) 31 (53.4)
Drug shortage 0 (0.0) 1 (0.9) 0 (0.0) 1 (1.7)
Drug toxicity 36 (31.0) 23 (19.7) 24 (38.1) 12 (20.7)
Patient request 6 (5.2) 6 (5.1) 5 (7.9) 4 (6.9)
Patient on active surveillance 0 (0.0) 2 (1.7) 0 (0.0) 2 (3.4)
Patient to receive surgery/radiation 2 (1.7) 4 (3.4) 1 (1.6) 2 (3.4)
Patient too ill for further chemotherapy 10 (8.6) 9 (7.7) 7 (11.1) 6 (10.3)
Patient on Coumadin 1 (0.9) 0 (0.0) 1 (1.6) 0 (0.0)
Maintenance therapy
Received maintenance 103 (44.6) 42 (21.0) 67 (48.9) 20 (21.3)
Reasons for no maintenance therapy after induction
(if mentioned) in those without maintenance
Disease progression 75 (58.6) 76 (48.1) 34 (48.6) 30 (40.5)
Patient on active surveillance 20 (15.6) 48 (30.4) 12 (17.1) 24 (32.4)
Patient request 4 (3.1) 3 (1.9) 4 (5.7) 3 (4.1)
Patient too ill for further chemotherapy 10 (7.8) 20 (12.7) 7 (10.0) 11 (14.9)
Unknown 19 (14.8) 11 (7.0) 13 (18.6) 6 (8.1)
Discontinued maintenance therapy 93 (90.3) 33 (78.6) 59 (88.1) 15 (75.0)
Reasons for discontinuation
Disease progression 74 (79.6) 27 (81.8) 45 (76.3) 11 (73.3)
Toxicity 7 (7.5) 1 (3.0) 5 (8.5) 0 (0.0)
Patient request 5 (5.4) 2 (6.1) 2 (3.4) 1 (6.7)
Patient on active surveillance 5 (5.4) 1 (3.0) 5 (8.5) 1 (6.7)
Patient too ill for further chemotherapy 1 (1.1) 2 (6.1) 1 (1.7) 2 (13.3)
Patient to receive surgery 1 (1.1) 0 (0.0) 1 (1.7) 0 (0.0)
Maintenance agents (% of those with maintenance)
Bevacizumab 83 (80.6) 4 (9.5) 55 (82.1) 2 (10.0)
Carboplatin 3 (2.9) 7 (16.7) 2 (3.0) 3 (15.0)
Paclitaxel 0 (0.0) 3 (7.1) 0 (0.0) 1 (5.0)
Erlotinib 10 (9.7) 9 (21.4) 5 (7.5) 4 (20.0)
Pemetrexed 16 (15.5) 21 (50.0) 9 (13.4) 10 (50.0)
Docetaxel 1 (1.0) 5 (11.9) 1 (1.5) 3 (15.0)
Gemcitabine 4 (3.9) 3 (7.1) 3 (4.5) 1 (5.0)
Vinorelbine 1 (1.0) 0 (0.0) 1 (1.5) 0 (0.0)
Other (cetuximab, cisplatin) 2 (1.9) 2 (4.8) 1 (1.5) 1 (5.0)
Second-line therapy
Received second-line 124 (53.7) 87 (43.5) 71 (51.8) 36 (38.3)
Second-line agents
Bevacizumab 39 (31.5) 11 (12.6) 22 (31.0) 6 (16.7)
Carboplatin 26 (21.0) 16 (18.4) 14 (19.7) 7 (19.4)
Paclitaxel 8 (6.5) 6 (6.9) 6 (8.5) 1 (2.8)
Erlotinib 31 (25.0) 15 (17.2) 21 (29.6) 9 (25.0)
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subpopulations (only data for elderly patients are shown in
Table 2).
Bev ? CP was associated with significantly longer
median PFS for the full study population compared with
the CP cohort (6.7 vs. 5.1 months; p = 0.041) (Fig. 2).
After adjusting for covariates in the Cox regression model,
Bev ? CP was associated with a 26 % reduction in the risk
of progression (HR 0.74; 95 % CI 0.59–0.92; p = 0.008).
Similar results for PFS were noted in the elderly and brain/
CNS metastases subpopulations but not in the ECOG PS
score C2 and anticoagulation subpopulations (Fig. 3).
Specifically, in the elderly subpopulation, treatment with
Bev ? CP was associated with a 35 % reduction in the risk
of progression, with a median PFS advantage of 1.8 months
compared with the CP cohort. The brain/CNS metastases
subpopulation had a 51 % reduction in risk of progression,
with a median PFS advantage of 2.1 months. Median PFS
advantage was B1 month in patients with an ECOG PS
score C2 and in the anticoagulation subpopulation.
Treatment with Bev ? CP was associated with signifi-
cantly longer median OS (by 2.9 months) over the CP
cohort (11.9 vs. 9.0 months; p\ 0.001) (Fig. 4). A sig-
nificantly lower proportion of the Bev ? CP cohort died
during follow-up compared with the CP cohort (72 vs. 80
%). After adjusting for covariates in the Cox PH model,






























Adjusted HR (95% CI): 0.74 (0.59, 0.92); 
P=0.008
Fig. 2 Kaplan–Meier progression-free survival curve by treatment
with vs without bevacizumab. B bevacizumab, CI confidence interval,
CP carboplatin ? paclitaxel, HR hazard ratio, PFS progression-free
survival
Table 2 continued









Pemetrexed 58 (46.8) 40 (46.0) 28 (39.4) 16 (44.4)
Docetaxel 5 (4.0) 7 (8.0) 2 (2.8) 2 (5.6)
Gemcitabine 16 (12.9) 15 (17.2) 9 (12.7) 4 (11.1)
Vinorelbine 1 (0.8) 2 (2.3) 1 (1.4) 2 (5.6)
Other (temozolomide, methotrexate, vinflunine,
clinical trial drug)
8 (6.5) 12 (13.8) 4 (5.6) 4 (11.1)
Data are presented as n (%)
BEV bevacizumab, CP carboplatin ? paclitaxel
a Represents those who discontinued prior to completion of all planned induction cycles
Fig. 3 Adjusted hazard ratios
for progression-free and overall
survival in study
subpopulations. CNS central
nervous system, ECOG Eastern
Cooperative Oncology Group
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in the risk of death (HR 0.57; 95 % CI 0.44–0.73; p\
0.001). Similarly, an OS advantage was found in the
elderly and brain/CNS metastases subpopulations, with
significant adjusted risk reductions of 46 % (median OS
12.3 vs. 8.3 months, respectively; p = 0.001) and 62 %
(median OS 11.3 vs. 9 months, respectively; p= 0.010)
(Fig. 3). Similar to PFS, a trend for longer survival was
noted in the Bev ? CP cohort in patients with an ECOG PS
C2 and in the anticoagulation subpopulations, but the dif-
ference was not statistically significant.
4 Discussion
The present study provides real-world evidence of the
effectiveness of using bevacizumab in combination with
carboplatin and paclitaxel as first-line therapy for
advanced/metastatic NS-NSCLC. Treatment with Bev ?
CP was associated with a significantly longer median PFS
by*2 months and median OS by 3 months compared with
treatment with CP alone. Furthermore, in subset analyses,
there remained a statistically significant improvement in
median PFS and OS for patients treated with bevacizumab
who were aged C65 years and for those who had brain/
CNS metastases at initiation of therapy. Although sufficient
evidence is available from clinical trials of the efficacy of
bevacizumab, there is limited evidence for key subpopu-
lations because of clinical trials excluding or under-repre-
senting vulnerable patient populations. The present study
included these vulnerable populations and suggests that
bevacizumab should be considered as first-line therapy in
advanced/metastatic NS-NSCLC in these patient
populations.
Specifically, in the elderly subpopulation of NS-NSCLC
patients, evidence has been conflicting. In the phase III
ECOG 4599 trial, which reported a median OS advantage
of 2 months with the addition of bevacizumab to CP,
subgroup analysis could not confirm that this advantage
was seen in patients aged C65 years [7]. In addition, a
pooled analysis of two phase III trials, ECOG 4599 and
PointBreak, found that the addition of bevacizumab to
chemotherapy backbone (CP in ECOG 4599 and carbo-
platin/pemetrexed in PointBreak) was associated with a
significant reduction in the risk of death for patients aged
\75 years; however, the analysis could not confirm this
benefit for the 157 patients across these two studies who
were aged C75 years [12]. A number of real-world eval-
uations have since attempted to further define the role of
bevacizumab in this population. The ARIES trial was a
prospective multicenter observational cohort study that
enrolled 1967 patients with advanced or metastatic NSCLC
who were receiving bevacizumab in combination with first-
line chemotherapy [13]. After adjusting for potential dif-
ferences in patient characteristics, the risk of progression
for older patients was similar to that for younger patients
(HR 1.01; 95 % CI 0.92–1.10 for patients aged C65 vs.
aged\65 years), but the risk of death was higher (HR 1.17;
95 % CI 1.06–1.28 for patients aged C65 vs. aged\65
years); however, given that all patients in this analysis
received bevacizumab, this study was not designed to
assess the benefit of bevacizumab added to chemotherapy
over chemotherapy alone for either group [13]. Langer
et al. [14] examined the addition of bevacizumab to
chemotherapy in a Medicare population of patients with
NS-NSCLC who were aged C65 years and found that
bevacizumab imparted a statistically significant benefit in
terms of OS for patients aged C65 years and for those aged
C75 years. However, Zhu et al. [15] conducted a large
population-based study using SEER data for Medicare
beneficiaries and could not confirm the effectiveness of
bevacizumab added to CP in the elderly subpopulation in
terms of survival advantage. In our study, in the elderly
subpopulation of 231 patients, treatment with Bev ? CP
was associated with a 4-month survival advantage versus
those who did not receive Bev ? CP. These findings are
consistent with both the meta-analysis of ECOG 4599 and
PointBreak and the real-world analysis by Langer and
colleagues [12, 14]. The discordance observed by the latter
analysis of Medicare patients may be explained by the
changing treatment patterns during the time frame in which
Zhu et al. [15] conducted their study versus Langer et al.
[14] and our analysis, resulting in an increased patient
selection in the elderly population receiving bevacizumab.
Zhu et al. [15] identified patients initiating bevacizumab in
2006 and 2007 (the first 2 years after approval of beva-
cizumab in the USA); of the 1502 patients treated with Bev
± CP, only 318 (21 %) received bevacizumab, and a
greater proportion of the bevacizumab arm had stage IV





























Adjusted HR (95% CI): 0.57 (0.44, 0.73); 
P<0.001
Fig. 4 Kaplan–Meier overall survival curve by treatment with vs
without bevacizumab. B bevacizumab, CI confidence interval, CP
carboplatin ? paclitaxel, HR hazard ratio, OS overall survival
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et al. [14] included a 4-year follow-up after the approval of
bevacizumab (2006–2009) and found that 35 % of the 1706
patients enrolled received bevacizumab; 74.2 and 73.6 %
of those treated with Bev ? CP and CP alone, respectively,
had stage IV disease.
Further, our study evaluated data from 2006 to 2013,
and key changes in treatment patterns also occurred dur-
ing this time frame that may have contributed to the
survival advantage of the Bev ? CP cohort in the elderly
subpopulation. During this time, Weiss et al. [16] exam-
ined second-line therapy in the elderly population; they
found it to have the same benefit as in their younger
counterparts. In our study, 51.8 % of patients aged C65
years went on to receive second-line therapy in the Bev ?
CP arm versus 38.3 % in the CP arm; pemetrexed was the
predominant therapy in this line. This is numerically
similar to that reported in the ECOG 4599 trial for the
bevacizumab cohort for the entire population (51 %),
although in the cohort of patients aged C75 years, more
patients in the non-bevacizumab cohort received post-
progression therapy (52 vs. 40 %) [12]. While Zhu et al.
[15] did not report these data, based on the timing of study
enrollment this may also have contributed to the differ-
ence in OS benefit seen in our population versus that
study.
Clinicians have been reluctant to use bevacizumab in
patients with brain/CNS metastases because of the risk of
hemorrhage. This imposes a real limit to the widespread
use of bevacizumab, as 25–30 % of patients with NSCLC
will ultimately be diagnosed with brain metastases, and this
is also often the first site of recurrence in patients initially
treated for early-stage disease [17]. Besse et al. [18]
reviewed clinical trial data to assess the risk of cerebral
hemorrhage in patients with CNS metastases treated with
bevacizumab for various solid tumors. Data from 187
(bevacizumab-treated, n = 91; non-bevacizumab-treated,
n = 96) patients were extracted from 13 randomized con-
trolled trials of patients who had undiagnosed CNS
metastases at therapy initiation or developed CNS metas-
tasis during treatment and hence were evaluable for a
safety analysis [18]. The rate of cerebral hemorrhage in the
bevacizumab-treated group was 3.3 vs. 1.0 % in those not
treated with bevacizumab [18]. In addition, this study also
analyzed two additional datasets (one obtained from two
single-arm, open-label safety studies that also excluded
CNS metastases at diagnosis and one obtained from two
studies that allowed patients with treated CNS metastases
to be included); 321 and 131 bevacizumab-treated patients
with CNS metastases from these two datasets, respectively,
were analyzed, with the rates of cerebral hemorrhage
reported at 0.9 and 0.8 %, respectively [18]. An observa-
tional cohort study, the ARIES trial, enrolled NSCLC
patients treated with bevacizumab in combination with
chemotherapy who were not represented in the larger
randomized controlled trials and found no reports of grade
3 or higher CNS bleeds in the 150 patients with CNS
metastases at baseline [19]. Additionally, a small phase II
trial [20] evaluated the efficacy and safety of bevacizumab
combination therapy in patients with NS-NSCLC and
asymptomatic untreated brain metastases. In the 67 patients
treated with first-line Bev ? CP, the median OS was 16.0
months (95 % CI 12–21), and no CNS bleeds were reported
[20]. In our study, treatment with Bev ? CP was associated
with a statistically significant increase of 2 months in
median OS versus treatment with CP. These data seem to
suggest that the presence of brain/CNS metastases should
not necessarily exclude patients from treatment with
bevacizumab.
As with all observational research, there are limitations
that must be considered to allow for valid interpretation of
the study findings. The key limitation is that of treatment
selection bias, with the relative contraindications for
bevacizumab (bleeding, brain metastases) increasing the
likelihood of patients with these conditions receiving CP.
Additionally, specifically with the elderly patients, physi-
cians are likely to select the healthiest patients for
aggressive systemic treatment with bevacizumab. While
the study did adjust for these differences in the Cox PH
models and also excluded patients who died or progressed
within the first 30 days, the nonrandomized nature of the
study does not likely fully account for the inherent treat-
ment selection bias. Additionally, concern regarding the
tolerability of a doublet platinum therapy in patient popu-
lations with an ECOG PS C2 may have contributed to the
rather small sample size for this subset. While data were
collected through a multimodal approach, it is still possible
that important data elements remained unavailable. For
example, some of the variables used as patient selection
criteria (e.g., non-squamous histology) may have been
missing from the data source, which would have resulted in
the exclusion of patients who would have otherwise been
eligible, or variables used to describe the eligible patient
population and variables used to classify patients into
subpopulations (e.g., ECOG PS) were not available for all
patients. Additionally, any healthcare utilization outside of
the oncology practices reporting to ION was not captured
for these patients (e.g., drugs administered or imaging
performed during hospitalizations, emergency department
visits, and primary care or non-oncology specialist visits),
and therefore indicators of progression or change in ther-
apy may not have been captured. However, while data
availability may have imposed some limitations on the
results, it is unlikely that the cohorts were differentially
biased by these data limitations.
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5 Conclusion
Based on this retrospective analysis, the addition of beva-
cizumab to CP is an effective treatment strategy for
patients with NS-NSCLC in terms of PFS and OS
improvement. Included in this analysis were patients tra-
ditionally excluded from bevacizumab therapy, and subset
analysis reveals that those patients with brain/CNS
metastases or aged C65 years maintain a statistically sig-
nificant benefit in terms of OS and PFS with the addition of
bevacizumab.
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